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Abstract
Modern medicine requires generalised approaches to the synthesis and integration
of multimodal data, often at different biological scales, that can be applied to a va-
riety of evidence structures, such as complex disease analyses and epidemiological
models. However, current methods are either slow and expensive, or ineffective
due to the inability to model the complex relationships between data modes which
differ in scale and format. We address these issues by proposing a cross-modal
deep learning architecture and co-attention mechanism to accurately model the
relationships between the different data modes. Differentiating Parkinson’s Dis-
ease (PD) patients from healthy patients forms the basis of the evaluation. The
model outperforms the previously published state-of-the-art unimodal analysis by
2.35 %, while also being 53 % more parameter efficient than the industry standard
cross-modal model. Furthermore, the evaluation of the attention coefficients allows
for qualitative insights to be obtained. Through the coupling with bioinformatics,
a novel link between the interferon-gamma-mediated pathway, DNA methylation
and PD was identified. We believe that our approach has general applications and
could optimise the process of medical evidence synthesis and decision making in
an actionable way.
1 Introduction
One of the biggest challenges facing the medical field is the ability to understand and diagnose
complex diseases. Complex diseases are caused by a combination of genetic, environmental and
lifestyle factors [1]. Understanding the influence of each of these factors requires the study of
biomedical data which can exist in drastically different biological scales and formats. Complex
disease analyses primarily focus on unimodal data and do not necessarily consider the interdependence
between the different modes of data available. This work aims to exploit these relationships through
the use of Machine Learning (ML) to diagnose, and gain data-driven insights into, complex diseases.
Cross-modal deep learning is a machine learning technique that utilises information obtained from
multiple different data sources, which all independently encode information about a specific outcome,
to obtain a greater understanding of the problem domain. Cross-modal models commonly use
specialist subnetworks to independently extract features from the different data modes, before
concatenating the features together to perform a final prediction. This approach has been successfully
used in audio-visual speech classification [2], object recognition [3], and cancer subtype classification
[4]. However, the shortfall of this approach is understanding the complex relationships between
data modes. This is due to the dependence on a final feed-forward neural network to model all
relationships between the independently extracted features in the concatenated latent space.
This work leverages off of cutting-edge research in Neural Machine Translation (NMT) and Visual
Question Answering (VQA) to propose a cross-modal model which focuses on better modelling these
complex relationships. Specifically, the model adapts the concepts of co-attention from VQA [5] to
multi-head self-attention from NMT [6] to present the Multi-Head Co-Attention (MHCA) model.
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Attention has previously shown benefits in cross-modal learning for graph structured data [7]. The
architecture proposed in this research is a generalised solution which places an emphasis on learning
a joint similarity distribution between the data modes, irrespective of the biological scales and format
of the input biomedical data.
Observing the attention weights further enables qualitative validation of the model predictions.
Interpretability is a dominant theme in ML for health [8, 9]. Existing solutions primarily focus on
independent modules which run in parallel to unimodal models monitoring the model properties,
producing statistically-based interpretations [10, 11, 12]. Whereas, the solution presented in this
work has the interpretability as an integral component of the model architecture.
Parkinson’s Disease (PD) is a complex neurodegenerative disorder which primarily affects the motor
functionality of a patient [13]. The cause of the disease is not yet well understood, resulting in
ineffective preventative and treatment measures. This has seen the incident and death rate of PD
increase year-on-year [14]. Consequently, PD is one of the most active areas of medical research.
There have been very few applications of ML in PD research. These applications either focus on
patient diagnosis [15] or symptom and biomarker identification [16, 17]. All of these applications
have only considered unimodal data, no focus has been placed on leveraging the diverse multimodal
data available. Therefore, PD is used as a case study for the remainder of this paper.
2 Dataset and Preprocessing
This study makes use of the brain SPECT images and corresponding DNA methylation (DNA-m)
data from the PPMI database1. SPECT images are 3-D images of the brain which are used to model
dopamine-transporter functionality, while DNA-m data is the only epigenetic marker for which a
detailed mechanism of mitotic inheritance has been described [18]. This provides a lifetime record of
an individual’s environmental exposures. The dataset consists of 121 healthy and 287 PD patients.
The SPECT images have the shape 91 × 109 × 91 and were co-registered and normalised to the
range [0, 1]. The DNA-m data has 765, 373 β-value features, filtered according to [19], in the range
[0, 1]. β-values are a ratio of intensities between methylated and unmethylated cytosine-guanine
dinucleotide (CpG) sites.
Feature selection, using the recursive feature selection algorithm with an XGBoost model, was used
to address the curse of dimensionality associated with the DNA-m data (see Appendix A for details).
This resulted in 441 highly predictive features. Upfront feature selection, as opposed to using a neural
network to generate a compressed latent representation of the original input, enabled interpretability
for the DNA-m data by allowing for a one-to-one mapping between attention weights and features.
3 Multi-Head Co-Attention Model Design
Figure 1 provides an overview of the MHCA model applied to the SPECT images, #»s , and DNA-m
data, #»m. Specialist encoder networks generate the keys,
#»
k , queries, #»q , and values, #»v , for the attention
mechanism, where the keys and values are the same. The MHCA mechanism generates the attention
coefficients, αq and αv, from the input keys and queries. These, coefficients are used to weight the
queries and values, producing
#»
q′ and
#»
v′, respectively. Residual connections are added to each of the
weighted outputs to account for information loss with the attention mechanism [20]. The weighted
outputs are then added together to generate the hidden representation
#»
h , a concept adapted from
VQA for co-attention mechanisms [5], and passed through a pointwise linear layer with sigmoid
activation to perform the final prediction. This highlights how the different data modes influence the
features extracted from one another instead of the features being extracted independently2.
3.1 Encoders
The encoder subnetworks extract important and correlated features between data modes and manipu-
late the output to be of the format features × embedding. The DNA-m encoder simply assigns an
embedding dimension of 64 to the input as the feature selection is done upfront.
1Data can be accessed at https://www.ppmi-info.org/, last accessed 15 August 2019.
2Code available at: https://github.com/Devin-Taylor/multi-head-co-attention
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Figure 1: Overview of the proposed MHCA model for two data modes, see text for symbol definitions.
Note, the proposed model is generalisable to different data modes.
The SPECT encoder consists of 3 blocks of a 3×3×3 convolution layer followed by a 2×2×2 max
pooling layer with ReLU activation [21]. Each convolution layer consisted of 16, 32, and 64 filters,
respectively. This was followed by a convolution layer with 64 filters and no activation function as it
is responsible for generating the SPECT features. The final output is of dimension 7× 9× 7× 64,
which is collapsed into the format 441× 64. The fact that the convolution and max pooling operators
maintain the spatial relationships between their inputs and outputs makes it possible to upsample the
attention weights back to the dimensions of the original inputs for interpretability.
3.2 Multi-Head Co-Attention Mechanism
The MHCA mechanism leverages the scaled dot-product attention from the Transformer network [6].
Equation 1 defines the similarity score between two features, eij , as a function of the dot product
between the SPECT features q = { #»q1, #»q2, · · · , #»qn} and the DNA-m features k = { #»k1, #»k2, · · · , # »kn},
and the feature dimensionality of the DNA-m, dk. Where T refers to the transpose operator.
eij =
#»qi
#»
kj
T
√
dk
(1)
The Transformer network [6] determines a single vector of attention coefficients from the similarity
matrix, as translation is directed. Given that cross-modal learning is not directed, this research
leverages the commutative property of the dot product operator to determine two vectors of attention
coefficients. This exploits the fact that the distribution of attention weights will likely be different
when looking from the keys to queries compared to the queries to keys. The attention coefficients
for the values (v = k = { #»v1, #»v2, · · · , # »vn}) and queries are defined in Equations 2 and 3, respectively.
The hidden space,
#»
h , is obtained by taking the sum of the weighted data modes,
#»
q′ and
#»
v′, and
residual connections as defined in Equation 4. LayerNorm is the layer normalisation operator [22].
αvij =
exp(eij)∑n
m=1 exp(eim)
(2) αqij =
exp(eTij)∑n
m=1 exp(e
T
im)
(3)
#»
hi = LayerNorm
 #»ki + n∑
j=1
αqij
#»qj
+
 #»qi + n∑
j=1
αvij
#»vj
 (4)
4 Experiments and Results
Experimentation is centred around classifying healthy patients from PD patients. The model is
compared to the unimodal XGBoost DNA-m model (see Appendix A), the unimodal SPECT encoder
network with a final linear layer (SpectNet), a cross-modal model which concatenates independently
extracted features together (ConcatNet), and the previously published State-Of-The-Art (SOTA) 3-D
CNN for PPMI PD classification [23]. The dataset was split into 80 % train and 20 % holdout test sets.
Three runs of 5-fold cross validation (CV) were performed for each experiment, where each fold is a
distinct split in the dataset. 10 % data augmentation was used for all experiments3. A batch size of 16,
Adam optimisation [24] with a learning rate of 3× 10−5, and 200 epochs were used. MHCA input
features were projected into four linear sub-spaces (heads). Table 1 presents the accuracy, AUROC,
and parameter count for each of the experiments. The results show the MHCA model improving on
3Augmentation achieved using multiaug library: https://github.com/Devin-Taylor/MultiAug
3
the SOTA results by 2.35 %, while also requiring 53 % fewer parameters than the ConcatNet model.
These results highlight the benefits of learning a joint similarity distribution in cross-modal learning.
Table 1: Accuracy, AUROC, and parameter count test set results. Mean and standard deviation for 3
runs of 5-fold CV presented. 3D-CNN results taken from literature due to lack of reproducibility.
Model DNA-m SPECT Accuracy (%) AUROC Parameter count
XGBoost 3 7 95.08± 0.00 0.917± 0.00 −
SpectNet 7 3 88.07± 2.54 0.879± 0.01 3, 793, 378
3D-CNN from [23] 7 3 96.00 − −
ConcatNet 3 3 97.12± 0.58 0.968± 0.00 3, 824, 066
MHCA 3 3 98.35 ± 0.58 0.976 ± 0.00 2,020,883
Qualitatively, Figure 2 provides slices from the different angles of the brain for a healthy and PD
patient. Notably, the weight masks validate existing research [25] by highlighting that the primary
differentiating factor in SPECT images is the dopaminergic cell loss that is associated with PD
patients. This is evident as the model focuses equally on both putamens (white regions) in the healthy
patient but only on the putamen without the apparent degradation in the PD patient.
(a) PD, top, 37/91.
(b) Healthy, top, 35/91.
(c) PD, back, 62/109.
(d) Healthy, back, 60/109.
(e) PD, side, 50/91.
(f) Healthy, side, 52/91.
Figure 2: Patient samples with weight mask overlay. Top: PD patient, bottom: healthy patient. The
subcaptions are of the format: label, angle, volume slice number. Figures best observed in colour.
PD is commonly linked to environmental factors, hence DNA-m plays a fundamental role in under-
standing the gene-environment interactions [26]. To investigate these interactions the CpG sites that
the attention weights placed the most emphasis on were selected (136 sites). The Bioconductor R
package [27] was used to obtain the set of 90 genes corresponding to the sites. DAVID, a bioinformat-
ics tool, was used to determine the biological pathways relevant to the genes [28, 29]. This analysis
identified the interferon-gamma-mediated (IFN-γ) pathway, alternative splicing, and transcriptional
activator activity as the most important pathways. IFN-γ, with the highest p-value (2.6× 10−3), has
featured in recent studies linking gene expression data and the PD phenotype [30, 31, 32]. These
studies all focus on gene expression patterns, whereas this study presents the novel finding that links
IFN-γ to PD through DNA-m data. This finding is important as DNA-m patterns are considered more
reliable and stable than gene expression patterns. It also suggests that changes in DNA-m, as a result
of lifestyle, could influence the progression of PD. These results highlight how the interpretability
can be used to not only support patient diagnosis but also facilitate exploratory analyses of data.
5 Conclusion
A generalised cross-modal deep learning model for multimodal data with different biological scales
is presented. The model uses a novel co-attention mechanism to learn a joint similarity distribution
between data modes, thus better modelling the complex relationships between them. PD forms the
basis of the evaluation, exceeding the SOTA classification results by 2.35 %, while being 53 % more
parameter efficient. The model produced granular and informative interpretations, linking novel
biomarkers to the IFN-γ pathway. The results obtained highlight the value of attention in cross-modal
learning. Future work will focus on scalability and memory efficiency for higher-dimensional data,
and studying how perturbations to one data mode influence another data mode.
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A DNA-Methylation Preprocessing
This appendix provides additional information on the upfront feature selection process performed for the
DNA-methylation data, which is necessary for reproducing the results obtained in the main text.
Feature selection is a powerful machine learning technique which aims to reduce the number of features in
a dataset by selecting a subset of predictive features. Feature selection involves training a model, which has
built-in feature importance, to obtain a ranking of the features in terms of their predictive power. Thereafter, the
top n features are selected based on a user-defined metric.
An XGBoost model is used in this study. XGBoost is a popular gradient boosting algorithm with built-in
ensembling [33]. The model is popular for the ability to handle data with few samples, making it suitable for the
given application. The XGBoost model was combined with the Recursive Feature Elimination (RFE) algorithm
to perform the final feature selection. RFE is a recursive algorithm that trains an XGBoost model on the set
of available features. RFE then uses the feature importance from the XGBoost algorithm to remove a subset
of least predictive features. It repeats this process until a user-defined number of features are selected. RFE
is significantly more powerful than simply using the feature importance from a single XGBoost model as it
accounts for the fact that the importance of features might change in the presence or absence of other features.
The model was tasked on classifying Parkinson’s Disease patients from healthy patients using the PPMI dataset.
Table A.1 defines the hyperparameters for the models, obtained performing a parameter sweep. The number of
features to be selected by the RFE algorithm was set to 441 to ensure the dimensionality with the SPECT images
is consistent.
Table A.1: Hyperparameters for RFE XGBoost feature selection model.
Parameter Algorithm Value
learning_rate XGBoost 0.1
n_estimators XGBoost 100
max_depth XGBoost 6
min_child_weight XGBoost 2
gamma XGBoost 0
subsample XGBoost 0.8
colsample_bytree XGBoost 0.8
nthreads XGBoost 15
scale_pos_weight XGBoost 1
n_features_to_select RFE 441
step RFE 0.05
In order to validate that reducing the set of features did not negatively impact the data’s predictive power, the
XGBoost model was trained on the original dataset and on the reduced dataset. The dataset was split into 80 %
train and 20 % holdout test sets. The results obtained can be seen in Table A.2. Table A.2 shows that the reduced
set of features actually improved the results. This can be attributed to the unfiltered data suffering from the curse
of dimensionality. The reduced model forms a baseline for future comparisons.
Table A.2: Mean and standard deviation test set results for the XGBoost model before and after
feature selection using the RFE algorithm. Results are from 3 runs of 5-fold cross validation.
Number of
features
Accuracy (%) AUROC
765,373 67.21± 0.00 0.477± 0.00
441 95.08 ± 0.00 0.917 ± 0.00
7
